Hi everyone.
On 23/01/2023, our system had provided a few picks and the results are as below:
COP – (Buy) – Profit
COIN – (Buy) – Profit
NTLA (Buy) – Price Not Done
All three major stock indexes finished in the green on Monday, as pessimism among investors has faded in past days betting on the Fed’s slower tightening, ahead of busy earnings week. The Dow added 250 points after advancing more than 400 points during the session, while the S&P 500 roughly gained 1.2% and climbed above the 4000 mark. The Nasdaq 100 added 2%, as investors are eyeing earnings after tech firms shift their focus to cost cuts in recent weeks.
Let’s review our stock picks on Monday.
A call for buy for COP which resulted in profit. Our system entered the market at $122.54 and made a call to profit at $122.90, which is our trailing stop loss.
ConocoPhillips explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas (LNG), and natural gas liquids worldwide. It primarily engages in the conventional and tight oil reservoirs, shale gas, heavy oil, LNG, oil sands, and other production operations.
A call for buy for COIN which resulted in profit. Our system entered the market at $54.84 and made a call to profit at $55.40, which is our trailing stop loss.
Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. The company offers the primary financial account in the cryptoeconomy for retailers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable ecosystem partners to build crypto-based applications and securely accept crypto assets as payment.
A call for buy for NTLA which did not hit our price but was in the right direction. The market opened higher than our price and went upwards throughout the market.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
Stay tuned for more of our stock picks.
Want the next pick before it's written up?
AIRESCAN's AI publishes live recommendations in the app.